Can diabetes drug beat statins for fatty liver? new trial aims to find out

NCT ID NCT07180745

Not yet recruiting Disease control Sponsor: Badr University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study tests whether empagliflozin (a diabetes drug) works better than statins for treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. About 400 adults who are obese, diabetic, and have high cholesterol will take one of four treatments daily for 3 months. Researchers will measure liver fat and stiffness using a special ultrasound (FibroScan) and track side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Teaching hospital of Beni Suef University

Banī Suwayf, 62727, Egypt

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH)